Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The CDC and FDA advise against Ixchiq chikungunya vaccine for American travellers aged 60 and above. This is due to reported ...

NEW YORK (AP) — The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q1 2025 Results, Conference Call and Webcast. At this time all participants will be in a listen-only mode. After the speaker ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

European stock markets saw gains. Germany's DAX reached a record high. Investors felt relieved by signs of a possible ease in ...